LimFlow

Focus: LimFlow is a public biotech company focused on developing innovative treatment systems for critical limb ischemia, a severe vascular disease threatening limb loss. The company operates as a specialized device/biotech hybrid addressing an underserved patient population.

Profile data last refreshed 17h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About LimFlow

AI assessmentNot Hiring

No open roles listed right now. Follow LimFlow to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

LimFlow System

Critical Limb Ischemia

N/A

Clinical Trials (1)

NCT03124875PROMISE I Early Feasibility Trial of the LimFlow Stent Graft System

N/A

Help build intelligence for LimFlow

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline with 6 active programs all targeting critical limb ischemia, enabling deep clinical and commercial expertise in a high-need specialty
Public company status provides equity upside potential and greater financial transparency than private biotech counterparts
Innovative device/interventional approach (percutaneous deep vein arterialization, stent graft systems) differentiates from traditional pharma modalities

Watch Out For

Currently zero active job openings suggests company is in consolidation or restructuring phase, limiting hiring opportunities
Missing data on revenue, cash position, and R&D intensity raises questions about financial health and runway sustainability

Generated by Claude from LimFlow's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

LimFlow Stent Graft System

Critical Limb Ischemia

N/A

Clinical Trials (1)

NCT05313165PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

N/A

Percutaneous deep vein arterialization

Critical Limb Ischemia

N/A

Clinical Trials (1)

NCT03807661Percutaneous Deep Vein Arterialization Post-Market Study

N/A

Percutaneous deep vein arterialization

Critical Limb Ischemia

N/A

Clinical Trials (1)

NCT03321552PROMISE International

N/A

Natural Progression of High-Risk Chronic Limb-Threatening Ischemia: The CLariTI Study

Critical Limb Ischemia

N/A

Clinical Trials (1)

NCT04304105Natural Progression of High-Risk Chronic Limb-Threatening Ischemia: The CLariTI Study

N/A

LimFlow System

Critical Limb Ischemia

N/A

Clinical Trials (1)

NCT03970538PROMISE II: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 6 clinical trials

Top TAs: Cardiovascular

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Cardiovascular

2 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles